Insider Selling: Cellebrite DI (NASDAQ:CLBT) CMO Sells $49,109.28 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 4,323 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares of the company’s stock, valued at $1,536,792.16. This trade represents a 3.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Nicholas Gee also recently made the following trade(s):

• On Friday, August 21st, David Nicholas Gee sold 2,198 shares of Cellebrite DI stock. The shares were sold at an average price of $11.24, for a total value of $24,705.52.
• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total value of $3,696.10.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $12.29 on Friday. The firm has a market capitalization of $3.07 billion, a P/E ratio of 55.87, a P/E/G ratio of 1.78 and a beta of 1.18. The stock has a fifty day moving average price of $14.18 and a two-hundred day moving average price of $13.79. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.98.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Needham & Company LLC reduced their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday, August 14th. DA Davidson dropped their price objective on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Lake Street Capital cut their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Weiss Ratings downgraded Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Finally, JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $16.70.

Institutional Investors Weigh In On Cellebrite DI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Voss Capital LP boosted its position in Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after buying an additional 1,277,300 shares during the last quarter. Pertento Partners LLP boosted its holdings in Cellebrite DI by 28.2% in the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after acquiring an additional 1,311,109 shares during the last quarter. Invesco Ltd. boosted its holdings in Cellebrite DI by 0.8% in the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after acquiring an additional 43,041 shares during the last quarter. Granahan Investment Management LLC increased its position in Cellebrite DI by 16.3% in the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares during the period. Finally, Wellington Management Group LLP increased its position in Cellebrite DI by 93.7% in the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after purchasing an additional 1,475,579 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.